EXTON, Pa., Sept. 18 ViroPharma Incorporated(Nasdaq: VPHM) today announced that Michel de Rosen, president and chiefexecutive officer of ViroPharma, will present at the UBS Global Life SciencesConference at 4:00 P.M. ET on Tuesday, September 25, 2007. The conference isbeing held at the Grand Hyatt in New York.
ViroPharma's presentation will be webcast live for investors throughwww.viropharma.com and available through October 4, 2007.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to thedevelopment and commercialization of products that address serious diseasestreated by physician specialists and in hospital settings. ViroPharmacommercializes Vancocin(R), approved for oral administration for treatment ofantibiotic-associated pseudomembranous colitis caused by Clostridium difficileand enterocolitis caused by Staphylococcus aureus, includingmethicillin-resistant strains (for prescribing information, please downloadthe package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm).ViroPharma currently focuses its drug development activities in viral diseasesincluding cytomegalovirus (CMV) and hepatitis C (HCV). For more information onViroPharma, visit the company's website at www.viropharma.com.
SOURCE ViroPharma Incorporated